About Us

Altis’ mission is to provide scientific innovation, through collaborative relationships, by helping companies develop safer and more effective therapies to treat patients suffering from human disease.

Ben Scruggs, Ph.D.

Chief Executive Officer

Maureen Bunger, Ph.D, M.B.A.

Senior Director Marketing and Product Management

Jimmy Smedley, Ph.D.

President and Chief Operating Officer

Niki Heinz

Senior Director of Business Development

Ready to Go With Your Gut?

Contact us to learn more about RepliGut® Model Kits and Services.

Inflammatory bowel diseases (IBD) are a major health concern worldwide

Our Mission

Altis’ mission is to provide scientific innovation, through collaborative relationships, by helping companies develop safer and more effective therapies to treat patients suffering from human disease. We support life science researchers by providing expertise and unique in vitro platforms to further their research and increase their understanding of human biology, while reducing the need for animal testing.

Customer Focused
Quick replies

A need for better models

In order to successfully advance a novel therapy through the drug development pipeline, it is crucial to select an appropriate model system early on. Model systems provide us with valuable insights into disease mechanisms and enable effective evaluation of potential treatments. However, the current lack of user-friendly pre-clinical pharmacological testing models for the human intestine significantly hinders our ability to develop new therapies for intestinal disorders. Additionally, it presents a challenge in ensuring the safe passage of orally administered treatments for other conditions through the gut without  unwanted side effects.

Smiles guaranteed
World class service
Poster Presented at ISSX/DMDG meeting

Pioneering Technology

Altis Biosystems has pioneered the creation of Repligut® Systems, a collection of in vitro models derived from stem cells and designed specifically for pre-clinical drug discovery. These innovative systems overcome the constraints of conventional cell lines and animal models, providing a highly accurate representation of human intestinal physiology.

 

Harnessing the power of stem cells

Our flagship RepliGut® Planar models advance novel pharmaceuticals by harnessing the potential of human donor intestinal stem cells. These cells undergo a process of sequential proliferation and differentiation, ultimately transforming into the essential cell types found in the human gastrointestinal epithelium for use in drug discovery and development.

The RepliGut® model delivers valuable data insights, rapid screening capabilities, and an unparalleled biobank of ethically sourced donor intestinal cells, paving the way for more effective compound screening, disease modeling, and microbiome research.

Customer Focused
Quick replies
A,Liquid,Nitrogen,Bank,Containing,Suspension,Of,Stem,Cells.,Cell
medi-156-scaled.jpeg

Reducing the need for animal models

Our RepliGut® Models, which accurately replicate the complex cellular lifecycle of the intestinal crypt, provide an exceptional platform for numerous applications. Derived from various regions of the intestine, they allow for compound screening, disease modeling, drug disposition analysis, toxicity assessments, efficacy studies, and fundamental research investigations. With their human-derived physiologically-relevant capabilities, our models have the power to vastly reduce the dependence on animal studies, in line with the transforming landscape of pre-clinical drug discovery.

Through the replication of native human biology, our innovative intestinal stem cell platform delivers a wealth of physiologically relevant preclinical insights, ultimately enhancing the performance of clinical trials and diminishing the necessity for animal testing.
Smiles guaranteed
World class service

Ready to Go With Your Gut?

Contact us to learn more about RepliGut® Model Kits and Services.